Deep brain stimulation (DBS) has been used as a therapy for treating intractable pain since the 1960s. After the discovery of multiple cortico-striato-thalamo-cortical (CSTC) loops and that the malfunction of these loops occurs in Parkinson disease (PD) in 1980s, DBS has also been re-recognized as a treatment of central nervous system (CNS) loop circuit disease. Presently, DBS is widely used not only for treating PD or essential tremor, but also for other involuntary movement diseases, such as dystonia or ballism.
We have treated 138 patients with subthalamic nucleus (STN) -DBS for PD from 1998, and 26 of these STN-DBS cases have been followed up for more than 5 years. From the observation of these cases we noticed that STN-DBS is effective for treating the so-called dopa-related motor symptoms of PD, such as tremor and rigidity, but it is less effective for the so-called dopa-non-related motor symptoms of PD, such as gait and postural disturbance, speech or swallowing. Also, it is not effective for treating the non-motor symptoms of PD, such as psychiatric, cognitive or autonomic symptoms.
In our literature review, we found that the therapeutic efficacy and safety of two targets, the STN and globus pallidus pars interna (GPi) for PD have been continuously compared. Also an “early stim study” was published in which the therapeutic effect of STN-DBS was compared to that of the best medication in rather early stage of PD patients.
We successfully targeted the posterior subthalamic area (PSA) DBS for strong tremor patients and had success with Vo stimulation for a hereditary ballism patient ; two examples of the expanding surgical indications for DBS.
View full abstract